Customer Publication

Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration‐resistant prostate cancer

Authors: J. Semenas et al.

Journal: Molecular Oncology (2020)

Institution: Umeå University

Research Areas: Cancer research

Cell Lines: PC-3 (Human prostate adenocarcinoma cell line)

Summary: As there are limited treatment options for metastatic prostate cancer (PCa), the disease progresses to castration-resistant after the initial androgen-deprivation therapy. Thus, there is a need to develop new treatment strategies to effectively treat patients. In this study, J. Semenas with colleagues have developed a novel selective inhibitor (ISA-2011B), which exhibits specific effects towards subgroups of PCas alone and in combination with tamoxifen and can provide new therapeutic opportunities. Authors have used HoloMonitor M4 to study PC-3 cell morphology changes after drug treatment.

Keywords: HoloMonitor M4, Cell morphology, castration-resistant prostate cancer, estrogen receptor, PI3K/AKT pathway andtamoxifen, PIP5K1a, targeted therapy

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2